You are here

INTRACORONARY CU62 RADIATION THERAPY FOR RESTENOSIS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 2R44CA081349-02A1
Amount: $423,334.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
8018 EL RIO
HOUSTON, TX 77054
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JEFFREY LACY
 () -
Business Contact
Phone: (713) 747-7324
Email: PROTECINC@COMPUSERVE.COM
Research Institution
N/A
Abstract

DESCRIPTION: Percutaneous transluminal coronary angioplasty (PTCA) has become
the predominant treatment for symptomatic coronary atherosclerotic lesions.
Despite its prevalent use, this technique continues to be plagued by restenosis
rate of 40% with resultant enormous added health care costs and patient
morbidity. Radiation therapy applied locally at the site of coronary balloon
injury holds great promise to reduce this restenosis rate. All current and
proposed techniques of radiation delivery carry significant drawbacks of safety
and effectiveness of uniform dose application. This project proposes a unique,
novel approach to radiation delivery through utilization of short-lived
positron emitting isotope, Cu-62, produced by a generator system. This isotope
is delivered into the angioplasty balloon and provides the required radiation
with a brief and safe inflation time. Safety issues are addressed through use
of a Cu-62 chemical form assuring blood binding in the event of balloon rupture
combined with the short 9.7 minute half-life of Cu-62. Use of a balloon
provides significant advantages of uniformity of dose delivery and with Cu-62
is completely safe. In Phase I, an automated concentration system was developed
which coupled to the Zn-62/Cu-62 generator produced the highly concentrated
solution of Cu-62. This concentrator was employed in porcine overstretch injury
model of restenosis, which demonstrated the feasibility of safe use of
generator produced Cu-62 and also achieved a substantial reduction of
neointimal hyperplasia using a delivered dose of 25 Gy.

PROPOSED COMMERCIAL APPLICATION:
Not Available

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government